Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of “Buy” by Analysts

Shares of Rezolute, Inc. (NASDAQ:RZLT) have received a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $24.38.

A number of research firms recently commented on RZLT. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a report on Monday, February 10th. JMP Securities lifted their price target on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Thursday, February 13th.

Rezolute Stock Up 5.6 %

Shares of NASDAQ RZLT opened at $3.76 on Thursday. Rezolute has a twelve month low of $1.66 and a twelve month high of $6.19. The stock’s 50 day moving average price is $4.70 and its 200-day moving average price is $4.88. The company has a market capitalization of $227.61 million, a PE ratio of -3.08 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. As a group, research analysts expect that Rezolute will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans bought 10,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the chief financial officer now directly owns 150,900 shares of the company’s stock, valued at $647,361. The trade was a 7.10 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.39% of the company’s stock.

Institutional Investors Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock valued at $97,000 after purchasing an additional 6,470 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Rezolute during the 3rd quarter valued at $42,000. Charles Schwab Investment Management Inc. grew its position in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after purchasing an additional 9,000 shares in the last quarter. Virtu Financial LLC grew its position in shares of Rezolute by 58.0% during the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after purchasing an additional 9,551 shares in the last quarter. Finally, Alpine Global Management LLC purchased a new position in shares of Rezolute during the 4th quarter valued at $54,000. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.